Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 3/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6154523 | 1.00 | GPR119 (0.47) | GPR119DRD2BTKPDK1PDK2 | |
| SCHEMBL6156293 | 0.89 | DRD2 (0.52) | GPR119DRD2BTKPDK1PDK2 | |
| SCHEMBL6156298 | 0.89 | DRD2 (0.52) | GPR119DRD2BTKPDK1PDK2 | |
| SCHEMBL6156811 | 0.83 | BTK (0.51) | DRD2BTKKMT2AL3MBTL1JAK3 | |
| SCHEMBL6156813 | 0.83 | BTK (0.51) | DRD2BTKKMT2AL3MBTL1JAK3 | |
| SCHEMBL6156720 | 0.77 | GPR119 (0.49) | GPR119PDK1PDK2PDK3PDK4 | |
| SCHEMBL7182891 | 0.77 | DRD2 (0.52) | GPR119DRD2BTKAAK1KDM4D | |
| SCHEMBL7182896 | 0.77 | DRD2 (0.52) | GPR119DRD2BTKAAK1KDM4D | |
| SCHEMBL6154205 | 0.76 | GPR119 (0.54) | GPR119L3MBTL1 | |
| SCHEMBL30808779 | 0.74 | BTK (0.44) | GPR119DRD2BTKJAK3AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GPR119 279/4885DRD2 3058/4885BTK 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.